Your browser doesn't support javascript.
loading
Application of the international criteria for optic neuritis in the Acute Optic Neuritis Network.
Klyscz, Philipp; Asseyer, Susanna; Alonso, Ricardo; Bereuter, Charlotte; Bialer, Omer; Bick, Atira; Carta, Sara; Chen, John J; Cohen, Leila; Cohen-Tayar, Yamit; Contentti, Edgar Carnero; Dale, Russell C; Flanagan, Eoin P; Gernert, Jonathan A; Haas, Julian; Havla, Joachim; Heesen, Christoph; Hellmann, Mark; Levin, Netta; Lopez, Pablo; Lotan, Itay; Luis, Maria Belen; Mariotto, Sara; Mayer, Christina; Vergara, Alvaro Jose Mejia; Ocampo, Cassandra; Ochoa, Susana; Oertel, Frederike C; Olszewska, Maja; Uribe, José Luis Peralta; Sastre-Garriga, Jaume; Scocco, Dario; Ramanathan, Sudarshini; Rattanathamsakul, Natthapon; Shi, Fu-Dong; Shifa, Jemal; Simantov, Ilya; Siritho, Sasitorn; Tiosano, Alon; Tisavipat, Nanthaya; Torres, Isabel; Dembinsky, Adi Vaknin; Vidal-Jordana, Angela; Wilf-Yarkoni, Adi; Wu, Ti; Zamir, Sol; Zarco, Luis Alfonso; Zimmermann, Hanna G; Petzold, Axel; Paul, Friedemann.
Affiliation
  • Klyscz P; Experimental and Clinical Research Center, A Cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Asseyer S; Department of Neurology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Alonso R; Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.
  • Bereuter C; Neuroscience Clinical Research Center (NCRC), Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Bialer O; Experimental and Clinical Research Center, A Cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Bick A; Department of Neurology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Carta S; Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.
  • Chen JJ; Neuroscience Clinical Research Center (NCRC), Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Cohen L; University Center of MS and NMOSD, Neurology Department, Ramos Mejia Hospital, Buenos Aires, Argentina.
  • Cohen-Tayar Y; Experimental and Clinical Research Center, A Cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Contentti EC; Neuroscience Clinical Research Center (NCRC), Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Dale RC; Department of Neuro-Ophthalmology, Rabin Medical Center, Petah Tikva, Israel.
  • Flanagan EP; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Gernert JA; Department of Neurology, Hadassah Medical Center, Hebrew University, Jerusalem, Israel.
  • Haas J; Neurology Unit, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Verona, Italy.
  • Havla J; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Heesen C; Center for MS and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Hellmann M; Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA.
  • Levin N; University Center of MS and NMOSD, Neurology Department, Ramos Mejia Hospital, Buenos Aires, Argentina.
  • Lopez P; Department of Neuro-Ophthalmology, Rabin Medical Center, Petah Tikva, Israel.
  • Lotan I; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Luis MB; Eye Laboratory, Felsenstein Medical Research Center, Tel Aviv University, Tel Aviv, Israel.
  • Mariotto S; Neuroimmunology Unit, Department of Neuroscience, Hospital Aleman, Buenos Aires, Argentina.
  • Mayer C; TY Nelson Department of Paediatric Neurology, Children's Hospital at Westmead, Sydney, New South Wales, Australia.
  • Vergara AJM; Faculty of Medicine and Health and Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.
  • Ocampo C; Clinical Neuroimmunology Group, Kids Neuroscience Centre, Children's Hospital at Westmead, Sydney, New South Wales, Australia.
  • Ochoa S; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Oertel FC; Center for MS and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Olszewska M; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Uribe JLP; Institute of Clinical Neuroimmunology, LMU Hospital, Ludwig-Maximilians-Universität Munich, Munich, Germany.
  • Sastre-Garriga J; Experimental and Clinical Research Center, A Cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Scocco D; Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.
  • Ramanathan S; Neuroscience Clinical Research Center (NCRC), Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Rattanathamsakul N; Institute of Clinical Neuroimmunology, LMU Hospital, Ludwig-Maximilians-Universität Munich, Munich, Germany.
  • Shi FD; Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg Eppendorf, Hamburg, Germany.
  • Shifa J; Department of Neuro-Ophthalmology, Rabin Medical Center, Petah Tikva, Israel.
  • Simantov I; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Siritho S; Department of Neurology, Hadassah Medical Center, Hebrew University, Jerusalem, Israel.
  • Tiosano A; Neuroimmunology Unit, Department of Neuroscience, Hospital Aleman, Buenos Aires, Argentina.
  • Tisavipat N; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Torres I; Neuroimmunology Service, Department of Neurology, Rabin Medical Center, Petah Tikva, Israel.
  • Dembinsky AV; Neuromyelitis Optica Research Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Vidal-Jordana A; University Center of MS and NMOSD, Neurology Department, Ramos Mejia Hospital, Buenos Aires, Argentina.
  • Wilf-Yarkoni A; Neurology Unit, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Verona, Italy.
  • Wu T; Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg Eppendorf, Hamburg, Germany.
  • Zamir S; Ophthalmology Department, University of Florida, Gainesville, Florida, USA.
  • Zarco LA; Faculty of Medicine, University of Botswana, Gaborone, Botswana.
  • Zimmermann HG; University Center of MS and NMOSD, Neurology Department, Ramos Mejia Hospital, Buenos Aires, Argentina.
  • Petzold A; Experimental and Clinical Research Center, A Cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Paul F; Department of Neurology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Ann Clin Transl Neurol ; 2024 Aug 04.
Article in En | MEDLINE | ID: mdl-39099240
ABSTRACT

OBJECTIVE:

The first international consensus criteria for optic neuritis (ICON) were published in 2022. We applied these criteria to a prospective, global observational study of acute optic neuritis (ON).

METHODS:

We included 160 patients with a first-ever acute ON suggestive of a demyelinating CNS disease from the Acute Optic Neuritis Network (ACON). We applied the 2022 ICON to all participants and subsequently adjusted the ICON by replacing a missing relative afferent pupillary defect (RAPD) or dyschromatopsia if magnetic resonance imaging pathology of the optical nerve plus optical coherence tomography abnormalities or certain biomarkers are present.

RESULTS:

According to the 2022 ICON, 80 (50%) patients were classified as definite ON, 12 (7%) patients were classified as possible ON, and 68 (43%) as not ON (NON). The main reasons for classification as NON were absent RAPD (52 patients, 76%) or dyschromatopsia (49 patients, 72%). Distribution of underlying ON etiologies was as follows 78 (49%) patients had a single isolated ON, 41 (26%) patients were diagnosed with multiple sclerosis, 25 (16%) patients with myelin oligodendrocyte glycoprotein antibody-associated disease, and 15 (9%) with neuromyelitis optica spectrum disorder. The application of the adjusted ON criteria yielded a higher proportion of patients classified as ON (126 patients, 79%).

INTERPRETATION:

According to the 2022 ICON, almost half of the included patients in ACON did not fulfill the requirements for classification of definite or possible ON, particularly due to missing RAPD and dyschromatopsia. Thorough RAPD examination and formal color vision testing are critical to the application of the 2022 ICON.
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Ann Clin Transl Neurol Year: 2024 Document type: Article Affiliation country: Alemania Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Ann Clin Transl Neurol Year: 2024 Document type: Article Affiliation country: Alemania Country of publication: Estados Unidos